Navigation Links
Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
Date:10/2/2007

statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, the successful integration and consolidation of the Maine production facilities, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S. Securities and Exchange Commission.

Company Contact: Investor Contact:

Stan Fronczkowski Hayden Communications

Chief Financial Officer Brett Maas

(302) 456-6789 (646) 536-7331

http://www.sdix.com brett@haydenir.com


'/>"/>
SOURCE Strategic Diagnostics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Answerthink and LORENZ Life Sciences Group Announce Strategic Alliance for the SAP Life Science Industry
2. New Advances in Gastric Diagnostics: Smaller is Better
3. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
4. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
7. Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy
8. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
9. Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal Antibody IMC-A12 Presented at ASCO
10. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
11. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... tender offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary ... common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... , May 25 A record 235 new ... being developed by America,s pharmaceutical research and biotechnology companies, according to a ... , , ... adult population suffers from diabetes—a rate that has more than doubled since ...
... HELMOND, The Netherlands , May 25, 2010 Blue Medical ... life of,patients with cardiovascular disease, with the start of the PIONEER trial, in,which ... , , ... clinical program, is the trial that,enables for the first time the delivery of ...
Cached Medicine Technology:New Report Shows Record Number of Medicines Currently in Development to Treat Diabetes 2New Report Shows Record Number of Medicines Currently in Development to Treat Diabetes 3New Report Shows Record Number of Medicines Currently in Development to Treat Diabetes 4First Coronary Stent on Drug Eluting Balloon Implanted 2
(Date:4/15/2014)... RECIST Working Group published in the European Journal of ... categorization of tumor response or various aspects of progression could ... They found that modeling target lesion tumor growth did not ... of the other components of progression. The RECIST Working Group ...
(Date:4/14/2014)... been made in chemotherapy over the past decade, but ... continues to be a major challenge. , Nanotechnology ... the use of nanocarriers, or capsules, that can transport ... body. , The catch? These carriers are tiny, and ...
(Date:4/14/2014)... Henry Ford Hospital reached a medical milestone April 3, ... novel way to access the heart. , Henry Ford ... the unique procedure called transcaval valve replacement, which accesses ... Northern Michigan resident Viola Waller, 80, underwent Henry Ford,s ...
(Date:4/14/2014)... , , Penicillin, one of the scientific marvels of the ... it once won against bacterial infections. But scientists at ... new approach to restoring its combat effectiveness, even against ... the power of the penicillin family of drugs since ...
(Date:4/14/2014)... an active role in their radiation treatment decisions leaves ... may even relieve psychological distress around the experience, researchers ... University of Pennsylvania report in the journal ... undergoing radiation treatment, Neha Vapiwala, MD , an ...
Breaking Medicine News(10 mins):Health News:Can refined categorization improve prediction of patient survival in RECIST 1.1? 2Health News:Nano shake-up 2Health News:Henry Ford Hospital hits new heart valve surgery milestone 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 3Health News:Shared decision making during radiation therapy improves patient satisfaction 2Health News:Shared decision making during radiation therapy improves patient satisfaction 3
... Each year the American Institute of Biological Sciences ... contributions to the biological sciences. The AIBS ... to announce the following award winners for 2009: ... PhD, University of Washington, Outstanding Service Award: Robert ...
... Calif., May 15 Cord Blood America, Inc. (OTC ... preservation company ( http://www.cordblood-america.com ) ... cells to families nationwide and internationally, said today that ... In audio interview with analyst Francis Gaskins, explains the ...
... 15 The YWCA USA presented its prestigious 2009 ... Justice and YWCA Niagara for Women,s Economic Advancement at ... Washington, D.C. They were selected among six exemplary initiatives ... , , YWCA Central Massachusetts was honored ...
... Cigna Medical Group has announced the opening of its ... the total number of CareToday clinics to six.CareToday Anthem ... Daisy Mountain Drive and Gavilan Peak Parkway, 39510 North ... practitioners and physician assistants, the clinics offer after hours ...
... to be the fourth fatality in the U.S. , , FRIDAY, ... the swine flu outbreak has yet to run its current ... schools were closed Thursday after dozens of flu-like infections surfaced ... ventilator, according to published reports. , Meanwhile, a woman in ...
... with trastuzumab (Herceptin) to treat women who have metastatic ... their treatment options. , At the 45th Annual Meeting ... (ASCO), researchers from the Mayo Clinic campus ... vinorelbine, and trastuzumab offers a treatment option that is ...
Cached Medicine News:Health News:AIBS honors outstanding contributions to biology 2Health News:AIBS honors outstanding contributions to biology 3Health News:AIBS honors outstanding contributions to biology 4Health News:AIBS honors outstanding contributions to biology 5Health News:Cord Blood America CEO Matthew Schissler Expands on Thought Process in Owning Stem Cell Laboratory 2Health News:Cord Blood America CEO Matthew Schissler Expands on Thought Process in Owning Stem Cell Laboratory 3Health News:YWCA USA 2009 Hallmark Initiative Awards Presented to YWCA Central Massachusetts and YWCA Niagara 2Health News:Cigna Medical Group Announces Grand Opening of CareToday Clinic in Anthem, Ariz. 2Health News:Swine Flu Closes Three Schools in NYC 2Health News:Swine Flu Closes Three Schools in NYC 3Health News:Swine Flu Closes Three Schools in NYC 4Health News:Swine Flu Closes Three Schools in NYC 5Health News:Swine Flu Closes Three Schools in NYC 6Health News:Swine Flu Closes Three Schools in NYC 7Health News:Swine Flu Closes Three Schools in NYC 8Health News:Swine Flu Closes Three Schools in NYC 9Health News:Triple drug combination is promising option to treat metastatic HER2+ breast cancer 2Health News:Triple drug combination is promising option to treat metastatic HER2+ breast cancer 3
Shafts angled 45 degrees, 10 mm from tip to bend. 1 x 2 teeth. Serrated handle with polished finish. Most popular size or model....
Straight shafts with 5.5 mm tying platform and 1 mm crisscross serrated tips. Wide serrated handle with polished finish....
Serrated tips, straight platforms....
Curved shafts with fine pointed tips. Smooth handle with dull finish....
Medicine Products: